[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100643962":3},{"organization":4,"outcomesModule":7,"designInfo":28,"detailedDescription":11,"studyPopulation":11,"armGroups":34,"interventions":45,"overallOfficials":11,"centralContacts":55,"locations":61,"responsibleParty":77,"collaborators":11,"id":79,"slug":11,"hasResults":80,"nctId":81,"briefTitle":82,"officialTitle":83,"acronym":11,"eligibilityCriteria":84,"healthyVolunteers":80,"sex":85,"minAge":86,"maxAge":87,"enrollmentInfo":88,"targetDuration":11,"studyType":91,"phases":92,"briefSummary":95,"conditions":96,"keywords":11,"overallStatus":98,"whyStopped":11,"lastUpdateSubmitDate":99,"lastUpdatePostDateStruct":100,"startDateStruct":103,"completionDateStruct":105,"leadSponsor":107,"locationsCount":108},{"fullName":5,"class":6},"Peking Union Medical College Hospital","OTHER",{"primaryOutcomes":8,"secondaryOutcomes":13,"otherOutcomes":11},[9],{"measure":10,"description":11,"timeFrame":12},"Change from baseline in percent predicted FVC after 24 weeks of treatment (%)",null,"24 weeks",[14,17,19,21,23,25],{"measure":15,"description":11,"timeFrame":16},"Change in lymph node score as assessed by chest CT","24 weeks, 36 weeks and 48 weeks",{"measure":18,"description":11,"timeFrame":12},"Change from baseline in absolute FVC at 24 weeks of treatment (mL)",{"measure":20,"description":11,"timeFrame":12},"Change from baseline in percent predicted DLCO at 24 weeks of treatment (%)",{"measure":22,"description":11,"timeFrame":12},"Change from baseline in percent predicted FEV1 at 24 weeks of treatment (%)",{"measure":24,"description":11,"timeFrame":12},"Relapse rate of sarcoidosis at 24 weeks after treatment initiation",{"measure":26,"description":11,"timeFrame":27},"Relapse rate of sarcoidosis at 36 and 48 weeks after treatment initiation","36 weeks and 48 weeks",{"allocation":29,"interventionModel":30,"interventionModelDescription":11,"primaryPurpose":31,"observationalModel":11,"timePerspective":11,"maskingInfo":32},"RANDOMIZED","PARALLEL","TREATMENT",{"masking":33,"maskingDescription":11,"whoMasked":11},"NONE",[35,40],{"label":36,"type":37,"description":11,"interventionNames":38},"Oral Prednisone Group","ACTIVE_COMPARATOR",[39],"Drug: Prednisone",{"label":41,"type":42,"description":11,"interventionNames":43},"Intramuscular Compound Betamethasone Group","EXPERIMENTAL",[44],"Drug: Compound betamethasone",[46,51],{"type":47,"name":48,"description":49,"armGroupLabels":50,"otherNames":11},"DRUG","Prednisone","Prednisone, oral administration. Starting dose of 40 mg once daily for 2 weeks, followed by gradual tapering according to the following schedule: reduce by half a tablet (2.5 mg) each week. When the dose is reduced to 1 tablet (5 mg) once daily, maintain for 2 weeks; then reduce to half a tablet (2.5 mg) once daily for 2 weeks; then reduce to half a tablet (2.5 mg) every other day for 2 weeks; then reduce to half a tablet (2.5 mg) twice weekly for 2 weeks, then discontinue. Total treatment duration is 24 weeks.",[36],{"type":47,"name":52,"description":53,"armGroupLabels":54,"otherNames":11},"Compound betamethasone","Compound Betamethasone injection, administered intramuscularly. Each injection is 1 mL, given once every 4 weeks for a total of 6 injections, with a treatment period of 24 weeks.",[41],[56],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},"Hui Huang","CONTACT","86+13391587917","pumchhh@126.com",[62],{"facility":63,"status":11,"city":64,"state":65,"zip":66,"country":67,"countryCode":68,"cosmosGeoPoint":69,"geoPoint":74,"contacts":75},"Peking Union Medical College Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College","Beijing","Beijing Municipality","100730","China","CN",{"type":70,"coordinates":71},"Point",[72,73],116.39723,39.9075,{"lat":73,"lon":72},[76],{"name":57,"role":58,"phone":59,"phoneExt":11,"email":60},{"type":78,"investigatorFullName":11,"investigatorTitle":11,"investigatorAffiliation":11,"oldNameTitle":11,"oldOrganization":11},"SPONSOR","100643962",false,"NCT07668895","Evaluation of the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis","A Prospective, Multi-center, Randomized Controlled Clinical Trial to Evaluate the Efficacy and Safety of Compound Betamethasone in Pulmonary Sarcoidosis","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Diagnosed within the past 3 months with stage I-II (based on chest CT) treatment-naive pulmonary sarcoidosis, meeting the following: A. Histopathological diagnosis of sarcoidosis via tissue biopsy (bronchial mucosa, intrathoracic lymph nodes, lung, pleura, etc.) obtained during bronchoscopy; B. Chest HRCT showing mediastinal and hilar lymphadenopathy, with or without pulmonary infiltrates (nodules, patchy opacities, ground-glass opacities, etc.); C. CT stage confirmed independently by at least two experts in the field (among three experts reviewing the chest HRCT images).\n* Requiring systemic glucocorticoid therapy.\n* Able to complete scheduled follow-up visits.\n* Patient and family members understand the study protocol, are willing to participate in this study, and are able to provide written informed consent.\n\nExclusion Criteria:\n\n* Patient or family members are unable to understand the conditions and objectives of this study, or are unable to provide informed consent.\n* Subjects who cannot comply with the follow-up schedule as required by the protocol.\n* Presence of other serious diseases that, in the investigator's judgment, may affect patient safety or compliance.\n* Any significant clinical or laboratory abnormalities that, in the investigator's judgment, may affect safety evaluation.\n* Pregnant or breastfeeding women, or patients who cannot use effective contraception during the study period and within 3 months after the study ends.\n* Active malignancy requiring treatment (surgery, medical therapy, or radiotherapy).\n* Hypersensitivity to Diprospan (Compound Betamethasone) or prednisone.","ALL","18 Years","100 Years",{"count":89,"type":90},126,"ESTIMATED","INTERVENTIONAL",[93,94],"PHASE2","PHASE3","The goal of this clinical trial is to learn whether a study drug called Compound Betamethasone (also known as Diprospan) works to treat pulmonary sarcoidosis in people with early-stage disease (stage I or II). It will also learn about its safety compared to the standard treatment, prednisone.\n\nThe main questions it aims to answer are:\n\n* How much does the study drug improve lung function (measured by a test called FVC%) after 24 weeks of treatment?\n* How does it compare to prednisone in controlling symptoms, reducing chest lymph node swelling, and preventing relapse? Researchers will compare Compound Betamethasone injections (given once every 4 weeks) to prednisone pills (taken daily with a gradual dose reduction).\n\nParticipants will:\n\n* Receive either the study drug injection or prednisone pills for 24 weeks\n* Visit the clinic for checkups and lung function tests at weeks 6, 12, and 24\n* Have chest CT scans and blood tests to monitor their condition and any side effects\n* Be followed up for additional 24 weeks (up to week 48) to see if the disease comes back after treatment stops",[97],"Sarcoidosis, Pulmonary","NOT_YET_RECRUITING","2026-06-21",{"date":101,"type":102},"2026-06-25","ACTUAL",{"date":104,"type":90},"2026-07",{"date":106,"type":90},"2028-07",{"name":5,"class":6},1]